AstraZeneca’s Roxadustat And The Challenge Of Shifting Medicare Coverage Policy

Though the policy environment can be 'uncertain,' AstraZeneca has 'good grasp' on how the anemia drug for patients with chronic kidney disease will be covered under the Medicare end-stage renal disease bundled payment system, senior VP for market access Rick Suarez says.

Fuzzy man walking on hanging bridge vanishing in fog. Focus on middle of bridge.
Navigating A Shifting Environment

Prospective Medicare reimbursement for AstraZeneca PLC and FibroGen Inc.’s in-development roxadustat may look less generous in the future than it does now because of a recommendation being developed by the Medicare Payment Advisory Commission.

The companies filed for US Food and Drug Administration approval of roxadustat in December 2019. The first-of-its-kind oral drug for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet